Benzinga··Vandana SinghMerck Slashes Terns Pharma Offer to $53/Share After Trial Data Disappoints
Merck cut its Terns Pharmaceuticals offer to $53/share from $61 following disappointing TERN-701 trial data, with a competing bidder also withdrawing its offer.
MRKNVSTERNacquisitionclinical trial data